Genetically Modified T Cells Against Ovarian Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

December 31, 2029

Conditions

Ovarian Cancer

Interventions

BIOLOGICAL

OC-IgT cells

Autologous human OC-IgT cells.

Trial Locations (1)

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

All Listed Sponsors

lead

Shenzhen Geno-Immune Medical Institute

OTHER